| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
254,036,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$22.93 - $22.93 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Van Zoonen Marinus Johannes |
Pres., Europe/Intl&Glob. Mkt. |
• – – |
2010-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
17,721 |
17,721 |
|
- |
|
| Howard Alvin D |
Sr. V.P., Regulatory Affairs |
• – – |
2010-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
6,090 |
209,464 |
|
- |
|
| Reichel W Carl |
President, Pharmaceuticals |
• – – |
2010-01-21 |
4 |
AS |
$28.17 |
$116,070 |
D/D |
(4,120) |
732,522 |
|
- |
|
| Bruno Anthony D |
Exec. V.P., Corp. Development |
• – – |
2010-01-21 |
4 |
AS |
$28.17 |
$116,070 |
D/D |
(4,120) |
667,880 |
|
- |
|
| Boissonneault Roger M |
CEO & President |
• • – |
2010-01-21 |
4 |
AS |
$28.17 |
$384,779 |
D/D |
(13,658) |
1,934,050 |
|
- |
|
| Cross Leland H |
Senior V.P., Tech. Operations |
• – – |
2010-01-21 |
4 |
S |
$28.17 |
$29,637 |
D/D |
(1,052) |
339,226 |
|
- |
|
| Howard Alvin D |
Sr. V.P., Regulatory Affairs |
• – – |
2010-01-21 |
4 |
S |
$28.17 |
$34,286 |
D/D |
(1,217) |
203,374 |
|
- |
|
| Herendeen Paul |
Exec. V.P. and CFO |
• – – |
2010-01-21 |
4 |
S |
$28.17 |
$116,070 |
D/D |
(4,120) |
742,026 |
|
- |
|
| Ellman Herman |
Senior V.P., Clinical Devel. |
• – – |
2010-01-21 |
4 |
S |
$28.17 |
$32,736 |
D/D |
(1,162) |
225,000 |
|
- |
|
| Ellman Herman |
Senior V.P., Clinical Devel. |
• – – |
2010-01-11 |
4 |
S |
$28.32 |
$29,425 |
D/D |
(1,039) |
226,162 |
|
- |
|
| Howard Alvin D |
Sr. V.P., Regulatory Affairs |
• – – |
2010-01-11 |
4 |
S |
$28.32 |
$32,370 |
D/D |
(1,143) |
204,591 |
|
- |
|
| Cross Leland H |
Senior V.P., Tech. Operations |
• – – |
2010-01-11 |
4 |
S |
$28.32 |
$29,425 |
D/D |
(1,039) |
340,278 |
|
- |
|
| Alpinvest Partners Later Stage Co-Investments Cust |
*See Remarks |
– – • |
2009-11-25 |
4 |
S |
$22.25 |
$29,684,215 |
D/D |
(1,334,122) |
3,405,042 |
|
- |
|
| Credit Suisse First Boston |
10% Owner |
– – • |
2009-11-25 |
4 |
S |
$22.25 |
$97,378,304 |
I/I |
(4,376,553) |
35,102,682 |
|
- |
|
| Murray Stephen |
Director |
– • – |
2009-11-25 |
4 |
S |
$21.42 |
$90,505,853 |
I/I |
(4,226,145) |
33,819,259 |
|
- |
|
| Thomas H Lee Advisors Alternative V Ltd Ldc |
10% Owner |
– – • |
2009-11-25 |
4 |
S |
$22.25 |
$92,176,032 |
I/I |
(4,142,743) |
33,151,823 |
|
- |
|
| Thomas H Lee Alternative Fund V Lp |
10% Owner |
– – • |
2009-11-25 |
4 |
S |
$22.25 |
$72,394,981 |
D/D |
(3,253,707) |
26,037,402 |
|
- |
|
| Thl Advisors Alternative V Lp |
10% Owner |
– – • |
2009-11-25 |
4 |
S |
$22.25 |
$92,176,032 |
I/I |
(4,142,743) |
33,151,823 |
|
- |
|
| Abbrecht Todd M |
Director |
– • – |
2009-11-25 |
4 |
S |
$22.25 |
$92,544,514 |
I/I |
(4,159,304) |
33,284,358 |
|
- |
|
| Bcip Trust Associates Iii-B |
10% Owner |
– – • |
2009-11-25 |
4 |
S |
$22.25 |
$87,798,945 |
I/I |
(3,946,020) |
33,819,265 |
|
- |
|
| Connaughton John |
Director |
– • • |
2009-11-25 |
4 |
S |
$22.25 |
$87,798,945 |
I/I |
(3,946,020) |
33,819,265 |
|
- |
|
| Reichel W Carl |
President, Pharmaceuticals |
• – – |
2009-11-25 |
4 |
S |
$22.25 |
$397,608 |
I/I |
(17,870) |
71,508 |
|
- |
|
| Reichel W Carl |
President, Pharmaceuticals |
• – – |
2009-11-25 |
4 |
S |
$22.25 |
$3,263,141 |
D/D |
(146,658) |
736,642 |
|
- |
|
| Boissonneault Roger M |
CEO & President |
• • – |
2009-11-25 |
4 |
S |
$22.25 |
$5,140,507 |
I/I |
(231,034) |
300,000 |
|
- |
|
| Boissonneault Roger M |
CEO & President |
• • – |
2009-11-25 |
4 |
S |
$22.25 |
$2,040,370 |
D/D |
(91,702) |
1,947,708 |
|
- |
|
380 Records found
|
|
Page 12 of 16 |
|
|
